Press Release Overview
New Offerings from OPM Biosciences
OPM Biosciences has unveiled two innovative offerings aimed at supporting biosimilar developers: the Biosimilar Media Optimization Service and the Sureness™ Biosimilar Platform. These services enhance their existing OPM-CHO™ platform, which is designed for high-performance cell culture media and optimized for molecules in biosimilar development.
Key Features:
-
Biosimilar Media Optimization Service:
- Focuses on molecule-specific media development to improve critical quality attributes (CQAs) and productivity.
- Past projects yielded an average titer improvement of 81%, with some reaching over 150%.
-
Sureness Biosimilar Platform:
- Integrates media development with contract development and manufacturing organization (CDMO) capabilities.
- Supports the entire process from cell line and analytical characterization to regulatory submission.
Importance of Media in Biosimilars:
Cell culture media are crucial for optimizing cell growth and product quality, which is essential due to the increasing opportunities for biosimilar development stemming from patent expirations.
Company Background:
Based in Pleasanton, California, OPM Biosciences is leading advancements in cell culture and biologics development, offering next-generation media and comprehensive services that enhance biomanufacturing efficiency.
For more information, visit:
Media Contact:
Jessica Lin, Sr. Marketing Manager
Jessica.Lin@opmbiosciences.com
